- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02652000
Quality of Life After Permanent Interstitial Iodine Seed Prostate Brachytherapy
December 11, 2016 updated by: Daniel Rudolf Zwahlen, Kantonsspital Graubuenden
Retrospective Analysis of Quality of Life After Permanent Interstitial Iodine Seed Brachytherapy for Prostate Cancer
Retrospective study to analyze Quality of life in men after iodine seed brachytherapy for localized prostate cancer
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Retrospective Evaluation of Quality of life data collected on men who underwent iodine seed brachytherapy at the University Hospital Zurich
Study Type
Observational
Enrollment (Actual)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chur, Switzerland, 7000
- Kantonsspital Graubuenden, Department of Radiaton Oncology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
48 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Sampling Method
Non-Probability Sample
Study Population
Patients having had idodine seed brachytherapy for localized prostate cancer between 2009 and 2014
Description
Inclusion Criteria:
- Male > 18 years of age
- iodine seed brachytherapy for localized prostate cancer at the University Hospital Zurich
Exclusion Criteria:
- No iodine seed brachytherapy for localized prostate cancer at the University Hospital Zurich
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CTCAE v4.03ff Grade 1-4 Sexual/Reproductive Function
Time Frame: 5 years (2009-2014)
|
Scale
|
5 years (2009-2014)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CTCAE v4.03ff Grade 1-4 Gastrointestinal
Time Frame: 5 years (2009-2014)
|
Scale
|
5 years (2009-2014)
|
CTCAE v4.03ff Grade 1-4 Renal/Genitourinary
Time Frame: 5 years (2009-2014)
|
Scale
|
5 years (2009-2014)
|
International Prostate Symptom Score (IPSS)
Time Frame: 5 years (2009-2014)
|
Scale
|
5 years (2009-2014)
|
International Index of erectile function, five items (IIEF-5)
Time Frame: 5 years (2009-2014)
|
Scale
|
5 years (2009-2014)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Daniel R Zwahlen, MD, MBA, Kantonsspital Graubuenden
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2009
Primary Completion (Actual)
December 1, 2016
Study Completion (Actual)
December 1, 2016
Study Registration Dates
First Submitted
January 6, 2016
First Submitted That Met QC Criteria
January 7, 2016
First Posted (Estimate)
January 11, 2016
Study Record Updates
Last Update Posted (Estimate)
December 13, 2016
Last Update Submitted That Met QC Criteria
December 11, 2016
Last Verified
December 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KEK-ZH-Nr. 2015-0573
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms, Prostate
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedProstate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Roswell Park Cancer InstituteUniversity of PittsburghCompletedProstate Cancer | Prostate Neoplasms | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Cancer of ProstateUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)TerminatedMetastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate CancerUnited States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
DendreonCompletedProstate Cancer | Prostate Neoplasms | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Cancer of ProstateAustria, France, Netherlands, United Kingdom
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Institutes of Health (NIH)CompletedProstate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIB Prostate CancerUnited States
-
National Cancer Institute (NCI)CompletedProstate Adenocarcinoma | Stage I Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on No intervention in this retrospective study
-
Kantonsspital GraubuendenKlinik Hirslanden, ZurichCompletedNeoplasms, Second PrimarySwitzerland
-
Aga Khan University Hospital, PakistanCompleted
-
QuantalX NeuroscienceCompletedHealthy | Hemorrhage | Cognitive Impairment | Dementia | Fibromyalgia | TBI (Traumatic Brain Injury) | Cognitive Decline | Concussion, Brain | MS (Multiple Sclerosis) | Adhd | CVA | ABD | MciIsrael
-
Hadassah Medical OrganizationUnknownQuality of LifeIsrael
-
Johannes Gutenberg University MainzWithdrawn
-
Shanghai 10th People's HospitalUnknownBlood Pressure | Cardiovascular Risk Factor | Overall Mortality | Cardiovascular Mortality | Cardiovascular Events | Target Organ DamageChina
-
Instituto do Cancer do Estado de São PauloCompletedPhenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53 (BREAST-TP53)Breast Cancer | Li-Fraumeni Syndrome | TP53 R337H | Prognosis Breast CancerBrazil
-
National Taiwan University HospitalNational Science Council, TaiwanUnknownCarcinoma, Non-Small-Cell Lung | ChemotherapyTaiwan
-
National Taiwan University HospitalNational Science Council, TaiwanUnknown